Insight
August 25, 2026
In South Africa’s highly regulated pharmaceutical sector, compliance cannot operate effectively as a standalone legal function or as a response to a regulatory inspection. The nature of the industry demands something more integrated.
Increasing scrutiny by the South African Health Products Regulatory Authority (SAHPRA), alongside evolving governance, data protection and stakeholder expectations, means that legal and regulatory requirements need to form part of the way pharmaceutical businesses are designed and operated.
This is the principle behind compliance by design: Identifying legal and regulatory requirements at the point at which systems, processes and commercial decisions are developed, rather than attempting to remedy deficiencies once they have already arisen.
For pharmaceutical businesses, the consequences of getting this wrong can extend well beyond a regulatory penalty. Non-compliance may affect patient safety, product quality and efficacy, licensing, supply continuity and the reputation of the organisation. Depending on the circumstances, the consequences can include product recalls, regulatory action, litigation and potentially the suspension or loss of licences.
Compliance therefore needs to be understood as an operational and governance responsibility as much as a legal one.
A complex regulatory environment
South African pharmaceutical businesses operate within an extensive legislative and regulatory framework.
The Medicines and Related Substances Act 101 of 1965 regulates, among other things, the registration, manufacture, distribution, sale and marketing of medicines and scheduled substances. Pharmaceutical companies may also have obligations under the Protection of Personal Information Act 4 of 2013 (POPIA), the Consumer Protection Act 68 of 2008, the Companies Act 71 of 2008, occupational health and safety legislation, competition law and the various requirements and guidelines administered by SAHPRA.
Good Manufacturing Practice (GMP) requirements add a further operational layer, including expectations relating to quality management systems, documentation, validation, risk management and defined personnel responsibilities.
The difficulty arises when these obligations are dealt with separately from the underlying business processes. A system may function operationally but still create regulatory exposure because compliance requirements were considered only after implementation.
Compliance by design seeks to address that disconnect.
Moving compliance closer to the decision
Traditional compliance mechanisms such as audits, legal reviews and corrective actions remain important. They should, however, form part of a broader framework rather than serve as the primary means of identifying regulatory shortcomings.
A compliance-by-design approach moves legal and regulatory consideration closer to the point at which decisions are made.
This means considering compliance when operational procedures are developed, technology is procured or configured, suppliers are appointed, manufacturing systems are introduced and responsibilities are allocated within the business.
It also means recognising that compliance cannot belong exclusively to a legal or compliance department. Quality assurance, supply chain, information technology, research and development, procurement, human resources and executive leadership may each carry responsibility for aspects of the organisation’s regulatory position.
Several areas illustrate the importance of this integrated approach.
Governance and accountability
Effective compliance begins with clear responsibility and oversight.
Boards and executive teams need sufficient visibility of the organisation’s regulatory exposure, supported by appropriate reporting structures and escalation mechanisms. Regulatory developments and emerging compliance risks should form part of the organisation’s broader risk-management processes, with sufficient resources allocated to areas of material exposure.
This is particularly important in a sector in which an operational failure can quickly become a governance, regulatory and reputational issue.
Accountability should therefore be identifiable throughout the organisation. Employees should understand not only the requirements relevant to their roles, but also where responsibility lies when an issue arises.
Quality, manufacturing and the supply chain
Regulatory requirements are most effective when incorporated into manufacturing and quality processes at the design stage.
GMP requirements, validation protocols, document controls, deviation procedures and quality risk-management processes should form part of the operational workflow itself. Introducing these controls only after deficiencies have been identified can result in substantial remediation, disruption and cost.
The same principle applies beyond an organisation’s own facilities.
Pharmaceutical businesses increasingly rely on third-party manufacturers, distributors, wholesalers, logistics providers and technology suppliers. Outsourcing a function does not necessarily remove the organisation’s underlying regulatory exposure.
Supplier qualification, due diligence, contractual controls, ongoing monitoring and clearly allocated regulatory responsibilities should therefore form part of the management of third-party relationships from the outset.
Contracts are an important component of this process, but they cannot replace effective operational oversight.
Data protection and technology
Pharmaceutical businesses may process significant volumes of personal and, in many cases, sensitive information. This can include patient information, clinical trial data, adverse-event reports, healthcare professional information and employee records.
POPIA requires responsible parties to implement appropriate technical and organisational safeguards to protect personal information.
For pharmaceutical organisations, this makes data protection an important part of systems and process design. Access controls, information-retention practices, consent processes where relevant, cybersecurity measures and incident-response procedures should be considered when technology and data processes are introduced, rather than added later as a compliance overlay.
As pharmaceutical operations become increasingly dependent on interconnected systems and external technology providers, the relationship between regulatory compliance, data governance and cybersecurity is also becoming more significant.
From policy to organisational practice
No compliance framework can be sustained through policies alone.
Employees must understand the obligations relevant to their work and be able to identify and escalate concerns before they develop into more serious problems. Regular and relevant training, effective reporting channels, whistleblowing mechanisms and consistent accountability all contribute to this.
Leadership is equally important. Where compliance is treated as an administrative burden, that attitude is likely to filter through the organisation. Where it is incorporated into business decisions and operational planning, regulatory risk becomes easier to identify and manage.
For pharmaceutical businesses, compliance by design is therefore not about creating another layer of procedure. It is about ensuring that regulatory requirements are reflected in the systems, contracts, processes and decisions through which the business already operates.
A well-designed compliance framework can help an organisation identify risk earlier, reduce the need for expensive remediation and respond more effectively when regulatory requirements change.
More importantly, in an industry in which the consequences of failure can extend directly to patients and public health, it places compliance where it belongs: within the everyday operation and governance of the business.
